AB0241 FACTORS THAT DIFFERENTLY ASSOCIATE WITH THE RETENTION ON TARGETED THERAPY OF PATIENTS WITH RHEUMATOID ARTHRITIS
Authors: E. Zhilyaev, G. Lukina, E. Koltsova, K. Lytkina, E. Shmidt
Journal: Annals of the Rheumatic Diseases (2021)

Background: A personalized approach to prescribing targeted drugs implies the availability of data that can be used to suggest that a particular drug is better suited for a given patient than others. Retention on the treatment can be considered as an integral indicator of the acceptability of the drug in real practice. For the purposes of treatment personalization, the indicators that are associated with better retention on some drugs and with worse retention, or that do not have a clear association with retention on others, are of particular interest. Objectives: to identify predictors those are differently associated with retention on different targeted drugs for the treatment of rheumatoid arthritis. Methods: Data of the patients with rheumatoid arthritis (RA) from the Moscow Unified Register of Arthritis (MUAR) were used. The analysis includes episodes of treatment with biological or synthetic targeted drugs (tDMARDs) that continue or end during the patient’s follow-up in the registry. Within the framework of the Cox proportional risk regression model, significant independent predictors of tDMARDs cancellation were identified. These indicators were later considered as confounders. Further, in the generated linear regression risk model, all available indicators were tested for the presence of a statistically significant interaction with the factor of used tDMARD. Results: The study included 944 episodes of tDMARDs treatment (Table 1.) in 832 patients. The average age is 55.3 + 12.4 years. There were 131 males (16.1%). The average duration of the disease is 13.1 + 9.4 years. Smoking, family history of RA, and the nature of RA onset (acute or gradual) were identified as reliable mutually independent predictors of retention on tDMARDs treatment. As a result of the search for indicators that reliably interact with used tDMARD, patient’s reports of the association of the onset of arthritis 1) with symptoms of intestinal dyspepsia (p &lt; 0.001), 2) with genital inflammatory disease (p = 0.002) were revealed. Most strongly associated with factor 1) was retention on abatacept (ABA), rituximab (RIT), and tofacitinib (TOFA). The second indicator was most strongly associated with retention on ABA, adalimumab (ADA) and TOFA (Picture 1). Table 1. Description of treatment episodes included in the analysis ABA ADA CER ETAт GOL INF RIT TOC TOFA Total Number of episodes 175 150 34 186 8 55 130 113 93 944 Completed (%) 39 (22,3%) 51 (34,0%) 13 (38,2%) 55 (29,6%) 2 (25,0%) 39 (70,9%) 31 (23,8%) 14 (12,4%) 9 (9,7%) 253 (26,8%) Line of treatment 1 83 (47,4%) 24 (70,6%) 113 (60,8%) 120 (80,0%) 3 (37,5%) 50 (90,9%) 70 (61,9%) 66 (50,8%) 35 (37,6%) 564 (59,7%) 2 62 (35,4%) 6 (17,6%) 52 (28,0%) 24 (16,0%) 2 (25,0%) 4 (7,3%) 22 (19,5%) 39 (30,0%) 30 (32,3%) 241 (25,5%) 3 22 (12,6%) 1 (2,9%) 13 (7,0%) 6 (4,0%) 1 (12,5%) 1 (1,8%) 15 (13,3%) 21 (16,2%) 14 (15,1%) 94 (10,0%) &gt; 3 8 (4,6%) 3 (8,8%) 8 (4,3%) 0 (0,0%) 2 (25,0%) 0 (0,0%) 6 (5,3%) 4 (3,1%) 14 (15,1%) 45 (4,8%) ABA – abatacept, ADA – adalimumab, CER – certolizumab paegol, ETA- etanercept, GOL – golimumab, INF – infliximab, TOC- tocilizumab, TOFA – tofacitinib. Conclusion: Anamnestic indications of the association of the onset of rheumatoid arthritis with symptoms of intestinal dyspepsia and with preceding genital inflammation are differently associated with retention on different targeted drugs in patients with RA. These indicators can be used to personalize the treatment. Picture 1. Retention on the abatacept depending on the features of the onset of rheumatoid arthritis Disclosure of Interests: None declared